Director’s Report to the National Advisory Council on Drug Abuse Director’s Report to the National Advisory Council on Drug Abuse May 22, 2002 (Prepared.

Slides:



Advertisements
Similar presentations
National Perspective of Healthy People 2020 Penelope Slade-Sawyer, P.T., M.S.W. HHS Office of Disease Prevention and Health Promotion 18 th Annual Healthy.
Advertisements

No one left behind: Increased coverage, better programmes and maximum impact for key populations WHO Consolidated Guidelines on HIV Prevention, Diagnosis,
Overview of Outreach competencies Stephen J. Gumbley, MA, ACDP II Director, New England ATTC.
TM NCI’s Smoking Cessation Activities and Priorities: Discovery, Development and Delivery Scott J. Leischow, Ph.D. National Cancer Institute.
Current and Future Challenges in Designing Behavioral Interventions: From Randomized Trials to Community Implementation Gerontological Society of America.
EARLY AND MID-CAREER DEVELOPMENT OPPORTUNITIES JACQUELINE LLOYD, MSW, PHD NIH SUMMER INSTITUTE JULY 2012 NIIDA NATIONAL INSTITUTE ON DRUG ABUSE.
What’s NIH? National Cancer Institute National Eye Institute National Heart, Lung, and Blood Inst. National Human Genome Research Inst National Institute.
Principles of Drug Addiction Treatment: What Works with Offenders? Rita Dries July 2006.
Nationals HIV/AIDS Strategy and how the mission of Women Accepting Responsibility, Inc. is helping to meet this goal. By She’kell Hutchinson Program Director,
Translating Research to Practice in Treating Substance Use Disorders Richard Rawson, Ph. D. UCLA Drug Abuse Research Center Matrix Institute on Addictions.
HIV and Hepatitis C in non- MSM Rural Communities: Issues and Interventions Shari Wells-Weiss, CASAC Director of Prevention Services Southern Tier AIDS.
Motivational Interviewing to Improve Treatment Engagement and Outcome* The effect of one session on retention Research findings from the NIDA Clinical.
Grant Writing1 Grant Writing Lecture What are the major types of grants available in mental health research? What is the process of grant preparation and.
Director’s Report to the National Advisory Council on Drug Abuse Director’s Report to the National Advisory Council on Drug Abuse May 22, 2003.
Division of AIDS, Behavioral and Population Sciences Risk, Prevention and Health Behavior IRG August, 2014 Reorganization/Realignment of RPHB Addictive.
HIV and Behavioral Health: An Update from SAMHSA Elinore F. McCance-Katz, MD, PhD Chief Medical Officer Substance Abuse and Mental Health Services Administration.
Institutes’ Areas of Interest. National Cancer Institute.
NIH R-36 Application Drug Abuse Dissertation Research: Epidemiology, Prevention, Treatment, Services, and/or Women and Sex/Gender Differences
TYPE 2 TRANSLATIONAL RESEARCH 2009 GRANT PROGRAMS UW Institute for Clinical and Translational Research (ICTR) Community-Academic Partnership Core (CAP)
Science for Global Health: Fostering International Collaboration Norka Ruiz Bravo,PhD Special Advisor to the Director National Institutes of Health U.S.
1 Department of Health and Human Services (DHHS) Substance Abuse & Mental Health Services Administration (SAMHSA) Center for Substance Abuse Prevention.
06/17/09 Eunice Kennedy Shriver National Institute of Child Health and Human Development NICHD HIV Research Scientific Priorities Lynne Mofenson MD, Branch.
Jacques Normand, Ph.D. Director, AIDS Research Program National Institute on Drug Abuse NIDA’s New HIV/AIDS Research Program.
Program Collaboration and Service Integration: An NCHHSTP Green paper Kevin Fenton, M.D., Ph.D., F.F.P.H. Director National Center for HIV/AIDS, Viral.
NIDA/SAMHSA Blending Initiative Overview. Advances in science are giving us a broad range of promising options for treating substance use disorders, BUT.
NIH U-01 Application Limited Competition: Women’s Interagency HIV Study (WIHS-V)
FUTURE HIV RESEARCH EFFORTS PLANNED FOR THE CLINICAL TRIALS NETWORK James L. Sorensen, Ph.D. Susan Tross, Ph.D. Raul Mandler, M.D. University of California,
KENTUCKY YOUTH FIRST Grant Period August July
Interamerican College of Physicians and Surgeons.
Overview of NIDA Funding Opportunities and Grant Funding Tips Bethany Griffin Deeds, Ph.D., M.A. Deputy Chief, Epidemiology Research Branch Division of.
EVALUATING THE IMPACT OF ADDING THE RECLAIMING FUTURES APPROACH TO JUVENILE TREATMENT DRUG COURTS: RECLAIMING FUTURES/JUVENILE DRUG COURT EVALUATION Josephine.
Understanding TASC Marc Harrington, LPC, LCASI Case Developer Region 4 TASC Robin Cuellar, CCJP, CSAC Buncombe County.
NCTSN Military Family Program: Building Partnerships with the National Child Traumatic Stress Network (NCTSN)
PREVENTION RESEARCH 2001 PREVENTION RESEARCH BRANCH The Staff: Liz Robertson, Ph.D., Chief Liz Robertson, Ph.D., Chief Susan David, M.P.H., Deputy Chief.
Elizabeth WellsDennis Daley School of Social WorkWestern Psychiatric Institute University of WashingtonUniversity of Pittsbu rgh Supported by Grants #
Baltimore Buprenorphine Initiative Advancing Recovery Project Baltimore City, Maryland January 14, 2010.
Federally Qualified Health Centers (FQHCs): Addressing the Challenges of Health Care Reform Community Treatment Program (CTP) Caucus Clinical Trials Network.
PRINCIPLES OF DRUG ADDICTION TREATMENT Dr. K. S. NJUGUNA.
Slide 1 Community Networks to Reduce Cancer Health Disparities Pre-Application Conference May 26, 2004 Bethesda, MD Kenneth C. Chu, PhD Chief, Disparities.
Raymond F. Anton, MD for The COMBINE Study Research Group
Belinda Seto, Ph.D. Acting Deputy Director for Extramural Research National Institutes of Health Human Subjects Research Enhancements Awards Renaissance.
Central Pennsylvania Center of Excellence to Improve Pregnancy Outcome Botti JJ, Weisman CS, Hillemeier MA, Baker SA The Central Pennsylvania Center of.
Clinical Loan Repayment Program. Public Health Improvement Act (P.L ) Title II, Clinical Research Enhancement Act Included requirement for the.
Building Sustainable Community-Linked Infrastructure to Enable Health Science Research (RC4) RFA OD Pre-application workshop October 23, 2009.
TARGETED CAPACITY EXPANSION PROGRAM: SUBSTANCE ABUSE TREATMENT FOR RACIAL/ ETHNIC MINORITY POPULATIONS AT HIGH RISK FOR HIV/AIDS.
How Does Trauma contribute to Substance Abuse and HIV Infection Among Ethnic Women Gail E. Wyatt, Ph.D. Professor, UCLA Department of Psychiatry and Biobehavioral.
Identifying and Implementing Evidence-Based Substance Abuse Services Charles G. Curie, M.S.W., A.C.S.W. Administrator, Substance Abuse & Mental Health.
Ryan White All Grantees Meeting Washington, DC November, 2012 Supporting National HIV/AIDS Strategies: the domestic experience and the AETCs.
Maryland’s Cigarette Restitution Program Georges C. Benjamin, MD FACP, Secretary Maryland Department of Health and Mental Hygiene November 2000 Protecting.
1 Session 3 Treatment and Recovery Treatment and Recovery.
Cedar Mountain Center Trends and Developments in Substance Abuse Treatment Kim Fletcher Marketing Director.
1 THE NIDA NATIONAL PREVENTION RESEARCH INITIATIVE NIDA Advisory Council February 20, 2002.
The Importance of a Strategic Plan to Eliminate Health Disparities 2008 eHealth Conference June 9, 2008 Yvonne T. Maddox, PhD Deputy Director Eunice Kennedy.
HIV Testing Strategies and Linkage to Care for Criminal Justice Populations Timothy P. Flanigan, MD Professor of Medicine Brown Medical School.
University of Kentucky Center for Clinical and Translational Science (CCTS) November 2015 Stephen W. Wyatt, DMD, MPH Senior Associate Director Center for.
Alcohol and AIDS: A New Decade Grantsmanship Workshop XIX International AIDS Conference Rome, Italy Kendall J. Bryant, Ph.D., NIAAA Alcohol and AIDS Research.
Update from the Division of Epidemiology, Services and Prevention Research Wilson M. Compton, M.D., M.P.E. Director, Division of Epidemiology, Services.
Cleveland Municipal Drug Court: SAMHSA CSAT Adult Treatment Drug Court Grant Dr. Margaret Baughman Madison Wheeler, BS Paul Tuschman, BA Begun.
Michael Sesma, Ph.D. National Institute of Mental Health Early Stage Investigators and the Program Perspective.
Research Directions and Update from the NIA Basil Eldadah Division of Geriatrics and Clinical Gerontology NIA.
DIVISION OF NEUROSCIENCE AND BEHAVIORAL RESEARCH (DNBR) NATIONAL ADVISORY COUNCIL ON DRUG ABUSE FEBRUARY 14, 2001 NIDA NATIONAL INSTITUTE ON DRUG ABUSE.
David M. Murray, Ph.D. Associate Director for Prevention Director, Office of Disease Prevention Multilevel Intervention Research Methodology September.
Science for Global Health: Fostering International Research Collaboration James Herrington, PhD, MPH Director Division of International Relations Fogarty.
Update from NIAAA Alcohol Prevention, Treatment, and Recovery Research
Driving Future Success with Current Investments in HIV Research
Screening, Brief Intervention and Referral to Treatment
Sherry Deren, Sung-Yeon Kang, Milton Mino & Honoria Guarino
Indiana Traumatic Brain Injury State Plan 2018 – 2023
No conflicts of interest
Behavioral and Social Science Research NIMH Division of AIDS Research
Presentation transcript:

Director’s Report to the National Advisory Council on Drug Abuse Director’s Report to the National Advisory Council on Drug Abuse May 22, 2002 (Prepared by Linda Thomas)

Overview of 1 st 172 days… 172 days… 10 hours… 10 hours… 14 minutes… 14 minutes… (but who’s counting?)

William Corrigall, Ph.D. - Chief, TRB, DNBR and Director, Nicotine and Tobacco Addiction Program William Corrigall, Ph.D. - Chief, TRB, DNBR and Director, Nicotine and Tobacco Addiction Program Ron A. Dobbins - CCTN Recent NIDA Staff Appointments Susan E. Martin, Ph.D. – DESPR Dawn Rabunsky – OPRM, CMB Dave Daubert – OPRM, MASB Charlotte Annan – OD/SPO Redonna Chandler, Ph.D. – DESPR Bev Pringle, Ph.D. – DESPR

Dr. Ahmed Elkashef - Physician Research of the Year Award from PHS Commissioned Corps Dr. Ahmed Elkashef - Physician Research of the Year Award from PHS Commissioned Corps Diana Haikalis – Letter of Appreciation Recent Staff Awards Debra Battle-Dudley – Letter of Appreciation Daisey Parker – Letter of Appreciation Deborah Wertz – Special Recognition Award

Director’s Report to the National Advisory Council on Drug Abuse Director’s Report to the National Advisory Council on Drug Abuse Highlights of Initiatives and Activities What’s Changing At NIDA? Future Directions

Highlights of NIDA Initiatives and Activities Highlights of NIDA Initiatives and Activities

“Neuroimaging Technology Development to Assess Brain and Behavior in Pediatric Populations” (RFA-DA ) “Neuroimaging Technology Development to Assess Brain and Behavior in Pediatric Populations” (RFA-DA ) 38 applications

National Prevention Research Initiative (NPRI) Basic Science In Prevention Research

New NIDA RFAs “NIDA National Prevention Research Initiative: Using Basic Science To Develop New Directions in Drug Abuse Prevention Research” (DA ) “NIDA National Prevention Research Initiative: Using Basic Science To Develop New Directions in Drug Abuse Prevention Research” (DA ) “NIDA National Prevention Research Initiative: Transdisciplinary Prevention Research Centers” (DA ) “NIDA National Prevention Research Initiative: Transdisciplinary Prevention Research Centers” (DA ) “Science Education NIDA National Prevention Research Initiative: Community Multi-Site Prevention Trials” (DA ) “Science Education NIDA National Prevention Research Initiative: Community Multi-Site Prevention Trials” (DA ) 31 applications 18 applications 5 applications

“National Criminal Justice Drug Abuse Treatment Research System” (RFA-DA ) “National Criminal Justice Drug Abuse Treatment Research System” (RFA-DA ) Issued: February 4, 2002 Application Receipt Date: May 13, 2002 Issued: February 4, 2002 Application Receipt Date: May 13, Applications

CTN “Expansion of the National Drug Abuse Treatment Clinical Trials Network” (RFA-DA ) “Expansion of the National Drug Abuse Treatment Clinical Trials Network” (RFA-DA ) 9 applications

“Modifying and Testing Efficacious Behavioral Therapies to Make Them More Community Friendly” (RFA-DA ) “Modifying and Testing Efficacious Behavioral Therapies to Make Them More Community Friendly” (RFA-DA ) 18 applications

“New Approaches to Prevent HIV/Other Infections in Drug Users” (RFA-DA ) “New Approaches to Prevent HIV/Other Infections in Drug Users” (RFA-DA ) 20 applications

“Hepatitis C Diagnosis, Treatment and Interaction with HIV/AIDS” (RFA-DA ) “Hepatitis C Diagnosis, Treatment and Interaction with HIV/AIDS” (RFA-DA ) 34 applications

Satellite Sessions for the XIV International AIDS Conference Satellite Sessions for the XIV International AIDS Conference Youth Drug Abuse and HIV Infection in Cultural Context Impact of Health Disparities on HIV Interventions in Drug- Using Populations Drug Abuse Treatment as HIV Prevention Effects of Drug Abuse and Sex Work on HIV Prevention Across National Borders HIV Risk Among Transgenders: The Social and Cultural Context of Substance Abuse Clarifying the Controversy About Whether Drug Abuse Influences AIDS Progression The Global Research Network on HIV Prevention in Drug- Using Populations Psychostimulant Abuse and HIV Risk Youth Drug Abuse and HIV Infection in Cultural Context Impact of Health Disparities on HIV Interventions in Drug- Using Populations Drug Abuse Treatment as HIV Prevention Effects of Drug Abuse and Sex Work on HIV Prevention Across National Borders HIV Risk Among Transgenders: The Social and Cultural Context of Substance Abuse Clarifying the Controversy About Whether Drug Abuse Influences AIDS Progression The Global Research Network on HIV Prevention in Drug- Using Populations Psychostimulant Abuse and HIV Risk

Released March 2002 Summary:  Prevention principles  Frequently asked questions  Epidemiology  NIDA’s major research programs Summary:  Prevention principles  Frequently asked questions  Epidemiology  NIDA’s major research programs

“Inhalant Abuse: Supporting Broad-Based Research Approaches” (RFA-DA ) “Inhalant Abuse: Supporting Broad-Based Research Approaches” (RFA-DA ) 30 applications

10 th Annual National Inhalants and Poisons Awareness Week (NIPAW) 10 th Annual National Inhalants and Poisons Awareness Week (NIPAW) Press Conference Participants (Mar. 13, 2002): NIDA – Dr. David Shurtleff ONDCP – John Walters SAMHSA – Charles Curie CSAT – Westley Clark CSAP – Elaine Parry Partnership for a Drug Free America – Stephen Pasierb National Inhalant Prevention Coalition – Harvey Weiss NIDA – Dr. David Shurtleff ONDCP – John Walters SAMHSA – Charles Curie CSAT – Westley Clark CSAP – Elaine Parry Partnership for a Drug Free America – Stephen Pasierb National Inhalant Prevention Coalition – Harvey Weiss

New NIDA PAs “Science Education Drug Abuse Partnership Award” (PA ) “Science Education Drug Abuse Partnership Award” (PA ) “Neuroscience Research on Drug Addiction” (PA ) “Neuroscience Research on Drug Addiction” (PA ) “Chemistry, Pharmacology, and Toxicology of Smoked Drugs of Abuse” (PA ) “Chemistry, Pharmacology, and Toxicology of Smoked Drugs of Abuse” (PA ) “Imaging – Science Track Award For Research Transition (I/START)” (PAR ) “Imaging – Science Track Award For Research Transition (I/START)” (PAR )

New PAs With Other NIH Components “Identifying Functional Links Between the Immune System and Brain Function Including Behavior” (PA ) “Identifying Functional Links Between the Immune System and Brain Function Including Behavior” (PA ) “Dissertation Research Grants for Underrepresented Minorities in the Ethical, Legal, and Social Implications (ELSI) of Genetic Research” (PA ) “Dissertation Research Grants for Underrepresented Minorities in the Ethical, Legal, and Social Implications (ELSI) of Genetic Research” (PA ) “Transitional Research Grants in Behavioral Science” (PA ) “Transitional Research Grants in Behavioral Science” (PA ) “Building Translational Research in Behavioral Science” (PAR ) “Building Translational Research in Behavioral Science” (PAR ) “Methodology and Measurement in the Behavioral and Social Sciences” (PAR ) “Methodology and Measurement in the Behavioral and Social Sciences” (PAR ) “Innovative Toxicology Models: SBIR/STTR” (PA ) “Mentored Clinical Scientists Development Program Award” (K12 AWARD) (PAR ) “Mentored Clinical Scientists Development Program Award” (K12 AWARD) (PAR )

New RFAs With Other NIH Components “Human Subjects Research Enhancements Program” (RFA-OD ) “Human Subjects Research Enhancements Program” (RFA-OD ) “Large-Scale Genotyping for the Haplotype Map of the Human Genome” (RFA-HG ) “Large-Scale Genotyping for the Haplotype Map of the Human Genome” (RFA-HG ) “Genetics in HIV/CNS Disease: Implications for Pathogenesis” (RFA-MH ) “Genetics in HIV/CNS Disease: Implications for Pathogenesis” (RFA-MH )

NIH Extramural Loan Repayment Program Regarding Clinical Researchers NIH Extramural Loan Repayment Program Regarding Clinical Researchers Educational loan repayment programs (LRP) for Clinical, Pediatric, Contraceptive and Infertility, and Health Disparities Researchers from a Disadvantaged Background Educational loan repayment programs (LRP) for Clinical, Pediatric, Contraceptive and Infertility, and Health Disparities Researchers from a Disadvantaged Background

NIH Extramural Loan Repayment Program Regarding Clinical Researchers NIH Extramural Loan Repayment Program Regarding Clinical Researchers Purpose: Recruitment and retention of highly qualified health professionals as clinical investigators; Participants contractually agree to engage in clinical research as extramural grantees or awardees Purpose: Recruitment and retention of highly qualified health professionals as clinical investigators; Participants contractually agree to engage in clinical research as extramural grantees or awardees Provides for the repayment of up to $35,000 of awardees’ loans for each year of obligated service Provides for the repayment of up to $35,000 of awardees’ loans for each year of obligated service We’ll Be Talking More About This Topic This Afternoon… We’ll Be Talking More About This Topic This Afternoon… (NIDA-26; NIH- >600)

Highlights of Recent Meetings and Events Highlights of Recent Meetings and Events

EIC NIDA RWJ EIC NIDA RWJ 7 th Annual PRISM AWARDS 7 th Annual PRISM AWARDS May 9, 2002 Sponsored by:

Other Recent Meetings/Events “Strategies to Improve the Replicability, Sustainability, and Durability of HIV Prevention Interventions for Drug Users” “Strategies to Improve the Replicability, Sustainability, and Durability of HIV Prevention Interventions for Drug Users” Special Events Program (at the Society for Research on Adolescence) Special Events Program (at the Society for Research on Adolescence) “Cardiovascular Complications of HIV (& Substance Abuse)” HIV/AIDS, Viral Hepatitis and Addiction: Perspectives on Prevention and Treatment” (at ASAM Meeting) HIV/AIDS, Viral Hepatitis and Addiction: Perspectives on Prevention and Treatment” (at ASAM Meeting) “Lapse and Relapse: The Chronic, Recurring Nature of Drug Addiction” “Lapse and Relapse: The Chronic, Recurring Nature of Drug Addiction” “Mental Health Research Issues in HIV Infection and Aging”

Meetings Continued Enhancing Outcomes in Women’s Health

Coming Soon… Objective: -enhance practical use of research and rapid adaptation into drug abuse treatment Objective: -enhance practical use of research and rapid adaptation into drug abuse treatment

What Is Changing at NIDA? What Is Changing at NIDA? NORMAL Redefined NORMAL Redefined

Administration Congress Communities Changes in Expectations TRANSLATION & ACCOUNTABILITY

ONDCP SAMHSA Other NIH Institutes (particularly NIAAA, NIMH, NINDS) Other NIH Institutes (particularly NIAAA, NIMH, NINDS) Changes in Relationships

ONDCP Goal: to decrease drug abuse by 10% in 2 yrs. & 25% in 5 yrs. Goal: to decrease drug abuse by 10% in 2 yrs. & 25% in 5 yrs. CTN Medications Development Medications Development SAMHSA ATTC TEST SCIENCE MOVE SCIENCE INTO COMMUNITIES MOVE SCIENCE INTO COMMUNITIES NIH NIDA Define Common Science Issues NIAAA, NIMH, NINDS, etc. NIAAA, NIMH, NINDS, etc. DO SCIENCE

Future Directions

DRUGS BRAIN MECHANISMS BEHAVIOR ENVIRONMENT HISTORICAL ENVIRONMENTAL - previous history - expectation - learning - social interactions - stress - conditioned stimuli - genetics - circadian rhythms - disease states - gender PHYSIOLOGICAL We Need to Study the Effects of All of These Factors & Their Interactions in the Development, Progression & Treatment of Drug Abuse and Addiction We Need to Study the Effects of All of These Factors & Their Interactions in the Development, Progression & Treatment of Drug Abuse and Addiction

Neuroscience and Behavioral Research Initiatives Neuroproteomics Mapping Functional Circuits in the Brain Neural Plasticity and Long Term Changes Protein Trafficking Novel Drug Development Stress & Drug Abuse Drug Abuse Relapse Social Cognitive Neuroscience HIV/AIDSNeuroproteomics Mapping Functional Circuits in the Brain Neural Plasticity and Long Term Changes Protein Trafficking Novel Drug Development Stress & Drug Abuse Drug Abuse Relapse Social Cognitive Neuroscience HIV/AIDS

Epidemiology, Prevention and Services Research Develop frameworks to identify environmental risk factors & gene-environment interactions Examine biological predictors of drug use/abuse Examine proximal influences to drug abuse Determine drug abuse trends in underserved areas Develop frameworks to identify environmental risk factors & gene-environment interactions Examine biological predictors of drug use/abuse Examine proximal influences to drug abuse Determine drug abuse trends in underserved areas Epidemiology Prevention Test interventions targeted to specific high-risk populations Test delivery models & systems for identification & intervention with a wide range of problem clusters Test interventions targeted to specific high-risk populations Test delivery models & systems for identification & intervention with a wide range of problem clusters

Epidemiology, Prevention and Services Research (continued) Services Develop laboratories for blending research & practice in different settings Test treatment and recovery models which account for the chronic illness concept Test alternative models for treating criminal justice- involved drug abusers Determine which components of the treatment delivery systems are effective for adolescent drug abusers Develop laboratories for blending research & practice in different settings Test treatment and recovery models which account for the chronic illness concept Test alternative models for treating criminal justice- involved drug abusers Determine which components of the treatment delivery systems are effective for adolescent drug abusers

Treatment Research and Development Develop and screen new compounds active at novel sites Increase collaboration with other NIH ICs and pharmaceutical companies for medication development Immunotherapy Guidance and retraining models for counselors and therapists Develop and screen new compounds active at novel sites Increase collaboration with other NIH ICs and pharmaceutical companies for medication development Immunotherapy Guidance and retraining models for counselors and therapists

CTN Expansion Additional Nodes RFA 2002 Military nodes “Developing” Nodes? Additional Sites CTPs with special features As needed Additional Nodes RFA 2002 Military nodes “Developing” Nodes? Additional Sites CTPs with special features As needed

CAMCODA –Street youth Social and disease related –Counseling and Testing Does it work well? CAMCODA –Street youth Social and disease related –Counseling and Testing Does it work well? Trans NIDA –International Research Rural Drug driven epidemics –Hepatitis C Treatment issues –Disabled populations Physically disabled Mentally disabled Developmentally disabled Trans NIDA –International Research Rural Drug driven epidemics –Hepatitis C Treatment issues –Disabled populations Physically disabled Mentally disabled Developmentally disabled CAMCODA TOPICS

Future Directions Future Directions We Want FEEDBACK! We Want FEEDBACK!

We Want Feedback On Philosophy Proposed Initiatives What we should be doing What we should not be doing